Compare Grab Holdings Ltd. (GRAB) vs Summit Therapeutics Inc (SMMT) Price & Performance

GRAB trades at $3.11, up 0.97% with a bearish technical signal despite strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying, though the stock faces technical headwinds with moving averages signaling bearish momentum.

GRAB's turnaround to profitability and Southeast Asian expansion present growth potential, but technical weakness and competitive pressures in ride-hailing create near-term uncertainty. The company's aggressive capital deployment and insider confidence suggest long-term optimism, though investors should monitor execution risks in financial services expansion.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.